NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free NRSN Stock Alerts $1.80 +0.08 (+4.34%) (As of 03:47 PM ET) Add Compare Share Share Today's Range$1.73▼$1.8550-Day Range$0.95▼$2.1152-Week Range$0.40▼$2.33Volume110,578 shsAverage Volume297,796 shsMarket Capitalization$24.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get NeuroSense Therapeutics alerts: Email Address Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About NeuroSense Therapeutics Stock (NASDAQ:NRSN)NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.Read More NRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRSN Stock News HeadlinesMarch 23, 2024 | morningstar.comNeuroSense Therapeutics Ltd NRSNFebruary 21, 2024 | finance.yahoo.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 21, 2024 | prnewswire.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 7, 2024 | finance.yahoo.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleJanuary 30, 2024 | finanznachrichten.deNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 30, 2024 | finance.yahoo.comNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 9, 2024 | finance.yahoo.comNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsMarch 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 4, 2024 | finance.yahoo.comNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementDecember 19, 2023 | investing.comNeurosense Therapeutics (NRSN) Earnings Dates & ReportsDecember 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)December 14, 2023 | finance.yahoo.comNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialDecember 8, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)December 6, 2023 | finance.yahoo.comWe're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn RateDecember 5, 2023 | marketwatch.comNeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares FallDecember 5, 2023 | markets.businessinsider.comNeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary EndpointsDecember 5, 2023 | msn.comNeuroSense ALS candidate meets key study goalsDecember 5, 2023 | finance.yahoo.comNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsDecember 4, 2023 | finance.yahoo.comNeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023November 28, 2023 | msn.comNeuroSense Therapeutics GAAP EPS of -$0.67November 28, 2023 | markets.businessinsider.comNeuroSense Therapeutics 9-Month Loss NarrowsNovember 28, 2023 | finance.yahoo.comNeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | markets.businessinsider.comNeuroSense Therapeutics Concludes Successful Type D Meeting With FDA For ALS TreatmentNovember 13, 2023 | finance.yahoo.comNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessNovember 6, 2023 | finance.yahoo.comNeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023November 1, 2023 | finance.yahoo.comNeuroSense Therapeutics to Participate in BIO-Europe FallSee More Headlines Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRSN CUSIPN/A CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-678.59% Return on Assets-174.61% Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book3.39Miscellaneous Outstanding Shares13,670,000Free Float9,922,000Market Cap$23.65 million OptionableNot Optionable Beta1.61 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Alon Ben-Noon (Age 45)Co-Founder, CEO & Director Comp: $619kMr. Or Eisenberg (Age 43)Chief Financial Officer Comp: $378kDr. Ferenc Tracik M.D. (Age 60)Chief Medical Officer Comp: $513kMs. Hagit Binder (Age 46)Chief Operation Officer Dr. Niva Russek-Blum Ph.D. (Age 45)Chief Technology Officer Ms. Yael Barak (Age 54)VP of Quality & Compliance Ms. Keren PushettHead of HRMr. Eidan LoushiC.R.A.More ExecutivesKey CompetitorsLumos PharmaNASDAQ:LUMOCytoMed TherapeuticsNASDAQ:GDTCIndaptus TherapeuticsNASDAQ:INDPTherapeuticsMDNASDAQ:TXMDCalciMedicaNASDAQ:CALCView All Competitors NRSN Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroSense Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRSN shares. View NRSN analyst ratings or view top-rated stocks. How have NRSN shares performed in 2024? NeuroSense Therapeutics' stock was trading at $0.7850 at the start of the year. Since then, NRSN shares have increased by 129.9% and is now trading at $1.8050. View the best growth stocks for 2024 here. Are investors shorting NeuroSense Therapeutics? NeuroSense Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 35,100 shares, a decrease of 83.4% from the February 29th total of 211,400 shares. Based on an average daily volume of 286,100 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.4% of the company's stock are sold short. View NeuroSense Therapeutics' Short Interest. When is NeuroSense Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Saturday, May 25th 2024. View our NRSN earnings forecast. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an IPO on Thursday, December 9th 2021. The company issued 2,000,000 shares at a price of $6.00-$7.00 per share. How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRSN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.